CRL vs. DGX

Last updated Jun 4, 2026

CRL (Charles River Laboratories International, Inc.) and DGX (Quest Diagnostics Incorporated) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. Over the past 10 years, CRL returned 7.68%/yr vs 11.82%/yr for DGX. At a 0.33 correlation, their price movements are largely independent.

Performance

CRL vs. DGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Charles River Laboratories International, Inc. (CRL) and Quest Diagnostics Incorporated (DGX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRL achieves a -9.83% return, which is significantly lower than DGX's 12.60% return. Over the past 10 years, CRL has underperformed DGX with an annualized return of 7.68%, while DGX has yielded a comparatively higher 11.82% annualized return.

CRL

• 1D: 2.91%
• 1M: 4.38%
• YTD: -9.83%
• 6M: -2.60%
• 1Y: 29.88%
• 3Y*: -3.58%
• 5Y*: -11.79%
• 10Y*: 7.68%

DGX

• 1D: 0.26%
• 1M: 1.13%
• YTD: 12.60%
• 6M: 7.01%
• 1Y: 13.58%
• 3Y*: 14.90%
• 5Y*: 10.63%
• 10Y*: 11.82%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CRL vs. DGX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CRL Charles River Laboratories International, Inc.	-9.83%	8.06%	-21.91%	8.49%	-42.17%	50.80%	63.56%	34.97%	3.41%	43.65%
DGX Quest Diagnostics Incorporated	12.60%	17.20%	11.77%	-10.05%	-7.80%	47.86%	14.11%	31.13%	-13.84%	9.16%

Correlation

The correlation between CRL and DGX is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.15
Correlation (3Y) Calculated over the trailing 3-year period	0.23
Correlation (5Y) Calculated over the trailing 5-year period	0.32
Correlation (10Y) Calculated over the trailing 10-year period	0.37
Correlation (All Time) Calculated using the full available price history since Jun 26, 2000	0.33

The correlation between CRL and DGX shifts across timeframes, from 0.15 (1 year) to 0.37 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CRL : $8.80B DGX : $21.69B
EPS CRL : -$3.75 DGX : $9.10
PS Ratio CRL : 2.20 DGX : 1.93
PB Ratio CRL : 2.99 DGX : 2.94
Total Revenue (TTM) CRL : $4.03B DGX : $11.28B
Gross Profit (TTM) CRL : $1.00B DGX : $3.75B
EBITDA (TTM) CRL : $737.05M DGX : $1.98B

Return for Risk

CRL vs. DGX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRL

CRL Risk / Return Rank: 59
CRL Sharpe Ratio Rank: 62
CRL Sortino Ratio Rank: 57
CRL Omega Ratio Rank: 58
CRL Calmar Ratio Rank: 59
CRL Martin Ratio Rank: 58

DGX

DGX Risk / Return Rank: 59
DGX Sharpe Ratio Rank: 60
DGX Sortino Ratio Rank: 55
DGX Omega Ratio Rank: 52
DGX Calmar Ratio Rank: 64
DGX Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRL vs. DGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and Quest Diagnostics Incorporated (DGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRL	DGX	Difference
Sharpe ratio Return per unit of total volatility	0.67	0.60	+0.06
Sortino ratio Return per unit of downside risk	1.17	1.08	+0.09
Omega ratio Gain probability vs. loss probability	1.15	1.13	+0.03
Calmar ratio Return relative to maximum drawdown	0.89	1.18	-0.29
Martin ratio Return relative to average drawdown	1.85	2.48	-0.63
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRL vs. DGX - Sharpe Ratio Comparison

The current CRL Sharpe Ratio is 0.67, which is comparable to the DGX Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of CRL and DGX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CRL	DGX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.67	0.60	+0.06
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.28	0.49	-0.77
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.20	0.50	-0.30
Sharpe Ratio (All Time) Calculated using the full available price history	0.24	0.53	-0.29

Drawdowns

CRL vs. DGX - Drawdown Comparison

The maximum CRL drawdown since its inception was -78.23%, which is greater than DGX's maximum drawdown of -49.46%. Use the drawdown chart below to compare losses from any high point for CRL and DGX.

Drawdown Indicators

	CRL	DGX	Difference
Max Drawdown Largest peak-to-trough decline	-78.23%	-49.46%	-28.77%
Max Drawdown (1Y) Largest decline over 1 year	-33.88%	-11.55%	-22.33%
Max Drawdown (3Y) Largest decline over 3 years	-63.52%	-16.57%	-46.95%
Max Drawdown (5Y) Largest decline over 5 years	-78.23%	-28.62%	-49.61%
Max Drawdown (10Y) Largest decline over 10 years	-78.23%	-36.60%	-41.63%
Current Drawdown Current decline from peak	-60.75%	-8.21%	-52.54%
Average Drawdown Average peak-to-trough decline	-25.72%	-11.90%	-13.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.23%	5.50%	+10.73%

Volatility

CRL vs. DGX - Volatility Comparison

Charles River Laboratories International, Inc. (CRL) has a higher volatility of 17.68% compared to Quest Diagnostics Incorporated (DGX) at 4.81%. This indicates that CRL's price experiences larger fluctuations and is considered to be riskier than DGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRL	DGX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.68%	4.81%	+12.87%
Volatility (6M) Calculated over the trailing 6-month period	34.98%	16.42%	+18.56%
Volatility (1Y) Calculated over the trailing 1-year period	44.98%	22.57%	+22.41%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	42.71%	21.73%	+20.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	37.74%	23.76%	+13.98%

Dividends

CRL vs. DGX - Dividend Comparison

CRL has not paid dividends to shareholders, while DGX's dividend yield for the trailing twelve months is around 1.68%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CRL Charles River Laboratories International, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DGX Quest Diagnostics Incorporated	1.68%	1.82%	1.96%	2.02%	1.66%	1.40%	1.85%	1.99%	2.34%	1.83%	1.72%	2.07%

Financials

CRL vs. DGX - Profitability Comparison

The chart below illustrates the profitability comparison between Charles River Laboratories International, Inc. and Quest Diagnostics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CRL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a gross profit of 0.00 and revenue of 995.83M. Therefore, the gross margin over that period was 0.0%.

DGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Quest Diagnostics Incorporated reported a gross profit of 942.00M and revenue of 2.90B. Therefore, the gross margin over that period was 32.5%.

CRL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported an operating income of 119.90M and revenue of 995.83M, resulting in an operating margin of 12.0%.

DGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Quest Diagnostics Incorporated reported an operating income of 399.00M and revenue of 2.90B, resulting in an operating margin of 13.8%.

CRL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Charles River Laboratories International, Inc. reported a net income of -14.84M and revenue of 995.83M, resulting in a net margin of -1.5%.

DGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Quest Diagnostics Incorporated reported a net income of 252.00M and revenue of 2.90B, resulting in a net margin of 8.7%.

Frequently Asked Questions

Can I hold both CRL and DGX in my portfolio?

CRL and DGX have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRL or DGX?

CRL has higher volatility (17.68%) compared to DGX (4.81%). In terms of maximum drawdown, CRL dropped -78.23% vs DGX's -49.46%.

Which has better risk-adjusted returns?

CRL currently has the higher Sharpe Ratio (0.67 vs 0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.